Authorized purpose: Assist trained interpreting physicians in analyzing breast-ultrasound images of patients with soft-tissue breast lesions suspicious for cancer who are referred for further diagnostic ultrasound examination.
Clinical role
User-in-the-loop lesion detection and characterization during image review; the user may query or replace ROIs, confirm or modify results, and save the findings to a structured report.
Images and patients
Mammography/DBT · Breast and suspicious soft-tissue breast lesions.
Key limitation
Keep in mind: Do not use on sites of post-surgical excision or images containing Doppler, elastography, or other overlays. It is not intended for primary interpretation of digital mammography or for mobile devices, and patient-management decisions should not rely solely on BU-CAD analysis.
Clinical detailsPurpose, workflow fit, evidence, and safety record
Workflow navigation pilot
Workflow role has not yet been reviewed for this navigation pilot.
A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources
What does this software do?Authorized purpose: Assist trained interpreting physicians in analyzing breast-ultrasound images of patients with soft-tissue breast lesions suspicious for cancer who are referred for further diagnostic ultrasound examination.
Which images or clinical context are in scope?Modality: Mammography/DBT Anatomy or clinical context: Breast and suspicious soft-tissue breast lesions. Input: DICOM breast-ultrasound images showing up to two orthogonal views of a single lesion. Ultrasound and full-field digital mammography can also be viewed, but the device is not for primary interpretation of digital mammography.
Who uses it?Intended users: Trained interpreting physicians.
What does the software produce?Output: ROIs and lesion contours; lesion-characteristics score from 0-100; BI-RADS categories 2, 3, 4a, 4b, 4c, or 5; BI-RADS shape, orientation, margin, echo-pattern, and posterior-feature descriptors; image measurements/documentation; and a structured report.
What is its most important limitation?Key limitation: Do not use on sites of post-surgical excision or images containing Doppler, elastography, or other overlays. It is not intended for primary interpretation of digital mammography or for mobile devices, and patient-management decisions should not rely solely on BU-CAD analysis.
Clinical takeaway. Clinical role: Assist trained interpreting physicians in analyzing breast-ultrasound images of patients with soft-tissue breast lesions suspicious for cancer who are referred for further diagnostic ultrasound examination.
Evidence takeaway. Evidence from the reviewed source record: FDA K210670 reports a 628-case retrospective fully crossed MRMC reader study with 16 readers (14 radiologists and 2 breast surgeons), including 456 U.S. and 172 Taiwan cases. Reader AUC_LROC was 0.7786 unaided versus 0.8160 aided, a 0.0374 shift (95% CI 0.0190-0.0557; p=0.0001). Aided-reader sensitivity was 93.53% (95% CI 90.50%-96.55%) and specificity 36.11% (95% CI 31.24%-40.98%). A separate 1,139-case standalone assessment reported AUC_LROC 0.8203; its sensitivity narrative states 88.53%, while Table 9 reports 88.33% (439/497; 95% CI 85.51%-91.15%) with wrong-location penalty, and specificity 57.94% (372/642; 95% CI 54.13%-61.76%). Lesion-identification accuracy 93.24% (1062/1139) used an ROI-center/50%-overlap objective and is not general diagnostic accuracy.
Evidence context
Evidence context not reviewed for this FDA record.
Public-label constraints
Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.
Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.
Purpose
Assist trained interpreting physicians in analyzing breast-ultrasound images of patients with soft-tissue breast lesions suspicious for cancer who are referred for further diagnostic ultrasound examination.
User-in-the-loop lesion detection and characterization during image review; the user may query or replace ROIs, confirm or modify results, and save the findings to a structured report.
DICOM breast-ultrasound images showing up to two orthogonal views of a single lesion. Ultrasound and full-field digital mammography can also be viewed, but the device is not for primary interpretation of digital mammography.
Do not use on sites of post-surgical excision or images containing Doppler, elastography, or other overlays. It is not intended for primary interpretation of digital mammography or for mobile devices, and patient-management decisions should not rely solely on BU-CAD analysis.
FDA K210670 reports a 628-case retrospective fully crossed MRMC reader study with 16 readers (14 radiologists and 2 breast surgeons), including 456 U.S. and 172 Taiwan cases. Reader AUC_LROC was 0.7786 unaided versus 0.8160 aided, a 0.0374 shift (95% CI 0.0190-0.0557; p=0.0001). Aided-reader sensitivity was 93.53% (95% CI 90.50%-96.55%) and specificity 36.11% (95% CI 31.24%-40.98%). A separate 1,139-case standalone assessment reported AUC_LROC 0.8203; its sensitivity narrative states 88.53%, while Table 9 reports 88.33% (439/497; 95% CI 85.51%-91.15%) with wrong-location penalty, and specificity 57.94% (372/642; 95% CI 54.13%-61.76%). Lesion-identification accuracy 93.24% (1062/1139) used an ROI-center/50%-overlap objective and is not general diagnostic accuracy.
Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.
Evidence summary
FDA K210670 reports a 628-case retrospective fully crossed MRMC reader study with 16 readers (14 radiologists and 2 breast surgeons), including 456 U.S. and 172 Taiwan cases. Reader AUC_LROC was 0.7786 unaided versus 0.8160 aided, a 0.0374 shift (95% CI 0.0190-0.0557; p=0.0001). Aided-reader sensitivity was 93.53% (95% CI 90.50%-96.55%) and specificity 36.11% (95% CI 31.24%-40.98%). A separate 1,139-case standalone assessment reported AUC_LROC 0.8203; its sensitivity narrative states 88.53%, while Table 9 reports 88.33% (439/497; 95% CI 85.51%-91.15%) with wrong-location penalty, and specificity 57.94% (372/642; 95% CI 54.13%-61.76%). Lesion-identification accuracy 93.24% (1062/1139) used an ROI-center/50%-overlap objective and is not general diagnostic accuracy.
Standalone BU-CAD sensitivity: FDA narrative 88.53%; Table 9 reports 88.33% (439/497, 95% CI 85.51%-91.15%) with wrong-location penalty. The separate 628-case aided-reader sensitivity was 93.53% (95% CI 90.50%-96.55%).
FDA source
Exact FDA submission
Checked 2026-09-09
The FDA packet contains a narrative/table discrepancy and distinct standalone versus aided-reader endpoints; they must not be collapsed into one sensitivity value.
Standalone BU-CAD specificity: 57.94% (372/642, 95% CI 54.13%-61.76%) with wrong-location penalty. The separate 628-case aided-reader specificity was 36.11% (95% CI 31.24%-40.98%).
FDA source
Exact FDA submission
Checked 2026-09-09
This removes the active-row mix of aided specificity and standalone sensitivity and preserves the endpoint, study, and wrong-location context.
No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.
BU-CAD regulatory performance study summary
DesignStand-alone performance and reader study (ACR AI Central category)
PopulationPopulation described in the exact-submission ACR model card
Scopeexact submission
Tested versionExact product version not reported; regulatory study summarized for FDA submission K210670
Samplen=1139
IndependenceIndependence not established
K210670
ACR AI Central summarizes the regulatory study; consult the exact FDA materials before comparative use.
Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.
Postmarket safety review
The exact-identifier FDA recall query returned no native recall record for K210670. This limited result does not establish absence of recalls or other safety information and does not cover later versions, family records, MAUDE reports, corrections, or field notices.
IT implementationDeployment, interfaces, data handling, and support
System and version relationships
Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.
No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.
Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.
Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner
No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.
Acquisition/source
Source context, not route validation: DICOM breast-ultrasound images showing up to two orthogonal views of a single lesion. Ultrasound and full-field digital mammography can also be viewed, but the device is not for primary interpretation of digital mammography.
Scope: Exact FDA submission.
Confirm scanner/model, protocol, series completeness and both software builds.
Source context, not route validation: The Viewer loads breast ultrasound and full-field digital mammography images from local storage or PACS; reports may be saved locally or uploaded to PACS, and CAD results can be exported to third-party reporting software. DICOM input/output is described, but exact interface versions and universal PACS/RIS/EHR compatibility are not established.
Scope: Exact FDA submission.
Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.
Unresolved route: Not established for the exact route.
Scope: Exact FDA submission. The exact FDA decision document was reviewed on 2026-11-14 and does not state where the subject device's software runs or how it is hosted. Confirm the deployment model, hosting, data flow, and current commercial configuration with the vendor.
Confirm processing location, queue ownership, exclusions and exact AI build.
Field checked 2026-11-14 ·
Returned objects
Source context, not route validation: ROIs and lesion contours; lesion-characteristics score from 0-100; BI-RADS categories 2, 3, 4a, 4b, 4c, or 5; BI-RADS shape, orientation, margin, echo-pattern, and posterior-feature descriptors; image measurements/documentation; and a structured report.
Scope: Exact FDA submission.
Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.
Unresolved route: ROIs and lesion contours; lesion-characteristics score from 0-100; BI-RADS categories 2, 3, 4a, 4b, 4c, or 5; BI-RADS shape, orientation, margin, echo-pattern, and posterior-feature descriptors; image measurements/documentation; and a structured report.
Scope: Exact FDA submission.
Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.
Unresolved route: Not established for the exact route.
Scope: Scope not established.
Name the local, platform and AI supplier support owners and escalation path.
Planned local route tests
No tests below have been performed or accepted.
Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.
Local implementation checklist
Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.
The Viewer loads breast ultrasound and full-field digital mammography images from local storage or PACS; reports may be saved locally or uploaded to PACS, and CAD results can be exported to third-party reporting software. DICOM input/output is described, but exact interface versions and universal PACS/RIS/EHR compatibility are not established.
Sources & review detailsFDA identity, research record, source ledger, and history
Regulatory identity
FDA record and catalog context
The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.
This audit distinguishes completed source review from fields that have not yet been researched.
Exact FDA record reviewedStatus
2026-09-20Last searched
25Fields reviewed
9Source classes checked
3Screened PubMed leads
1Screened trial leads
0Unreviewed FDA recall leads
The refreshed discovery snapshot contains 3 PubMed and 1 ClinicalTrials.gov candidate records. Discovery metadata alone does not establish exact tested-product, version, population, and endpoint applicability, so all candidates remain quarantined and none was promoted. The current discovery snapshot contains 3 PubMed and 1 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.
Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.
Source classes: fda ai list, fda decision summary, acr ai central product, fda device recall, literature index, trial registry, pubmed, clinical trials, openfda device recall
Field review details
Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.
Public pricing: Not verified - checked 2026-09-09 - Exact FDA submission
No public price or quote for the exact K210670 configuration was established in this review.
Pricing model: Not yet reviewed
Setup and integration fees: Not yet reviewed
Recurring fees: Not yet reviewed
Minimum commitment: Not yet reviewed
Contract duration: Not yet reviewed
Renewal terms: Not yet reviewed
Cancellation terms: Not yet reviewed
Support and service terms: Not yet reviewed
Trial or pilot terms: Not yet reviewed
Reimbursement: Not publicly available - checked 2026-09-09 - Exact FDA submission
No exact-product payer policy, coding instruction, or payment determination was established; eligibility must be evaluated by payer, site of service, and use case.
Deployment: Not publicly available - checked 2026-11-14 - Exact FDA submission
The exact FDA decision document was reviewed on 2026-11-14 and does not state where the subject device's software runs or how it is hosted. Confirm the deployment model, hosting, data flow, and current commercial configuration with the vendor.
Data hosting location: Not yet reviewed
Data retention: Not yet reviewed
Documented data use: Not yet reviewed
Hardware requirements: Not yet reviewed
Network requirements: Not yet reviewed
Identity and access: Not yet reviewed
Security: Not verified - checked 2026-09-09 - Exact FDA submission
Exact-release security controls, data retention, hosting boundaries, and scoped assurance documentation require vendor confirmation.
Installation timeline: Not yet reviewed
Training: Not verified - checked 2026-09-09 - Exact FDA submission
Current training prerequisites, competency checks, and support commitments for the exact configuration require vendor confirmation.
Monitoring: Not verified - checked 2026-09-09 - Exact FDA submission
Current drift, quality, uptime, alert, escalation, and incident-response commitments for the exact configuration require vendor confirmation.
Authorized purpose: Flags calcifications, masses, asymmetries and architectural distortions on compatible FFDM or DBT screening examinations; management must not be based solely on MammoScreen output.
Authorized purpose: BAC processes screening FFDM and DBT mammograms to detect the presence or absence of breast arterial calcifications at study and breast level and localize detected calcifications for qualified interpreting-physician review.
Authorized purpose: Tags screening cases as suspicious or blank to aid worklist prioritization; radiologists must review every examination and it does not mark original images.
Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.
Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.
Accepted repository change history
No entry has been added to this scoped change history for this record. This is not proof that the record never changed.